Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.

Detailed Description
-----------------
a more in-depth analysis of the different immune cell sub-populations as well as serum markers (cytokines) would provide a better understanding of post-allograft immune reconstitution mechanisms and identify potential immunologic biomarkers predictive of GVH or relapse.

Official Title
-----------------
Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions
-----------------
Malignant Hemopathy

Intervention / Treatment
-----------------
* Other: Blood samples (additional tubes from care) longitudinal
* Other: Blood samples (additional tubes from care) at inclusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Allogeneic hematopoietic stem cell transplant for hematological malignancy Patients 18 years of age or older Signed consent to participation Membership in a social security scheme, or beneficiary of such a scheme. Exclusion Criteria: A person of legal age subject to a legal protection measure (major under guardianship, curatorship or court bail), or unable to express consent (language criteria included).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Donor<br>In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. | Other: Blood samples (additional tubes from care) at inclusion<br>* In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made. In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.<br>|
| Receiver<br>Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used | Other: Blood samples (additional tubes from care) longitudinal<br>* Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation. | longitudinal study of the immune subpopulations of allografted patients for hematological malignancies. | 5 years after HSC transplantation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
malignant hemopathy, allogeneic hematopoietic stem cell transplant, blood collection